Soleno Stock Shoots Higher as Diazoxide Choline Gets US Orphan Drug Tag for Glycogen Storage Disease

  • The FDA has granted Orphan Drug Designation to Soleno Therapeutics Inc SLNO DCCR (diazoxide choline) Extended-Release tablets for the treatment of Glycogen Storage Disease Type 1a (GSD 1a), or von Gierke disease.
  • Von Gierke disease is a condition in which the body cannot break down glycogen. Glycogen is a form of sugar (glucose) that is stored in the liver and muscles. 
  • DCCR previously received Orphan Drug Designation for the treatment of Prader-Willi syndrome.
  • Orphan Drug Designation qualifies a candidate for various development incentives, including tax credits for eligible clinical trials, waiver of application fees, and market exclusivity for seven years upon FDA approval.
  • Price Action: SLNO shares are up 29.9% at $1.33 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefsOrphan Drug Designation
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!